Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunity and safety of IC51 (IXIARO, JESPECT) in pediatric population in non-endemic countries
2010-022266-27Phase 3Completed
- Sponsor
- Valneva
- Start
- Oct 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE), sponsored by Valneva. Primary endpoint: Seroprotection rate at 12 months after first IC51 vaccination. Started Oct 2010; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2010-022266-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022266-27.